Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of HEZKUE (Sildenafil) vs Viagra in Healthy Males
NCT06782659Phase 1Not yet recruiting
- Sponsor
- Aspargo Laboratories
- Start
- Jan 2025
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ASP-001 in erectile dysfunction (ED) (2 arms), sponsored by Aspargo Laboratories. Primary endpoints: Maximum Observed Plasma Concentration at 24 hours, Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration at 24 hours and 5 more. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
ASP-001
03
Conditions
erectile dysfunction (ED)
Beyond the preview
Go deeper on NCT06782659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06782659.